Literature DB >> 32228236

Revisiting the complement system in systemic lupus erythematosus.

Madhubala Sharma1, Pandiarajan Vignesh1, Karalanglin Tiewsoh1, Amit Rawat1.   

Abstract

Introduction: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease, characterized by the production of autoantibodies. Numerous mechanisms contribute to the pathogenesis and autoimmunity in SLE. One of the most important mechanisms is the defective function of the early complement components that are involved in clearing the immune-complexes and apoptotic debris. Major evidence supporting this hypothesis is the development of severe lupus in individuals with monogenic defects in any one of the early complement components such as C1q, C1 s, C1 r, C2, or C4.Areas covered: In this review, we discuss hereditary defects in classical complement components and their clinical manifestations, acquired defects of complements in lupus, the role of complements in the pathogenesis of antiphospholipid antibody syndrome and lupus nephritis, and laboratory assessment of complement components and their functions. Articles from the last 20 years were retrieved from PubMed for this purpose.Expert opinion: Complements have a dual role in the pathogenesis of SLE. On one hand, deficiency of complement components predisposes to lupus, while, on the other, excess complement activation plays a role in the organ damage. Understanding the intricacies of the role of complements in SLE can pave way for the development of targeted therapies.

Entities:  

Keywords:  Systemic lupus erythematosus; complement; diagnostics; monogenic defects; pathogenesis

Mesh:

Substances:

Year:  2020        PMID: 32228236     DOI: 10.1080/1744666X.2020.1745063

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  7 in total

1.  Primary Immunodeficiency in Children With Autoimmune Cytopenias: Retrospective 154-Patient Cohort.

Authors:  Emma Westermann-Clark; Cristina Adelia Meehan; Anna K Meyer; Joseph F Dasso; Devendra Amre; Maryssa Ellison; Bhumika Patel; Marisol Betensky; Charles Isaac Hauk; Jennifer Mayer; Jonathan Metts; Jennifer W Leiding; Panida Sriaroon; Ambuj Kumar; Irmel Ayala; Jolan E Walter
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

Review 2.  Epstein-Barr Virus and Systemic Autoimmune Diseases.

Authors:  Gunnar Houen; Nicole Hartwig Trier
Journal:  Front Immunol       Date:  2021-01-07       Impact factor: 7.561

3.  Peroxiredoxins as Markers of Oxidative Stress in IgA Nephropathy, Membranous Nephropathy and Lupus Nephritis.

Authors:  Natalia Krata; Bartosz Foroncewicz; Radosław Zagożdżon; Barbara Moszczuk; Magdalena Zielenkiewicz; Leszek Pączek; Krzysztof Mucha
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-12-16       Impact factor: 4.291

4.  Circulating Complement C1q as a Novel Biomarker is Associated with the Occurrence and Development of COPD.

Authors:  Ke Zhang; Kangkang Han; Hui Liu; Chunyan Zheng
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-02-23

5.  Successful Discontinuation of Eculizumab in a Pediatric Patient With Atypical Hemolytic Uremic Syndrome and Underlying Systematic Lupus Erythematosus.

Authors:  Issa Alhamoud; Sydney A Freiberg
Journal:  Cureus       Date:  2022-05-18

Review 6.  Revisiting B cell tolerance and autoantibodies in seropositive and seronegative autoimmune rheumatic disease (AIRD).

Authors:  J N Pouw; E F A Leijten; J M van Laar; M Boes
Journal:  Clin Exp Immunol       Date:  2020-11-15       Impact factor: 4.330

Review 7.  SLE: Novel Postulates for Therapeutic Options.

Authors:  Kinga K Hosszu; Alisa Valentino; Ellinor I Peerschke; Berhane Ghebrehiwet
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.